Qingdao Haier Biomedical (SHA:688139) terminated its plan to absorb and merge with subsidiary Shanghai RAAS Blood Products (SHE:002252).
The company cited the complexity of the transaction's structure for the termination, according to a Tuesday filing with the Shanghai bourse.
Shares of the biomedical cold chain storage manufacturer were down 11% in recent trade, while shares of Shanghai RAAS fell almost 6%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.